These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36524068)

  • 1. Extended use of rh-endostatin improves prognosis in patients with advanced non-small cell lung cancer: an analysis of retrospective study.
    Zhao J; Cheng Y; He L; Wang J; Xi Q; Gong C
    J Thorac Dis; 2022 Nov; 14(11):4416-4426. PubMed ID: 36524068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer.
    Liu X; Guo Z; Su L; Zuo A; Gao M; Ji X; Lu J; Yang S; Jiang Y; Lu D
    Invest New Drugs; 2024 Jun; 42(3):309-317. PubMed ID: 38700579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.
    Wang Z; Zhang H; Zhou C; Long X; Guan R; Yang N; Zhang Y
    Cancer Med; 2019 Apr; 8(4):1434-1441. PubMed ID: 30762300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
    Pu X; Wang Q; Liu L; Chen B; Li K; Zhou Y; Sheng Z; Liu P; Tang Y; Xu L; Li J; Kong Y; Xu F; Xu Y; Wu L
    Cancer Med; 2023 Apr; 12(7):7724-7733. PubMed ID: 36494905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
    Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
    Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer.
    Hu W; Fang J; Nie J; Dai L; Zhang J; Chen X; Ma X; Tian G; Wu D; Han S; Han J; Wang Y; Long J
    Medicine (Baltimore); 2016 Jul; 95(28):e4183. PubMed ID: 27428214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
    Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
    Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer.
    Lu S; Li L; Luo Y; Zhang L; Wu G; Chen Z; Huang C; Guo S; Zhang Y; Song X; Yu Y; Zhou C; Li W; Liao M; Li B; Xu L; Chen P; Hu C; Hu C
    J Thorac Oncol; 2015 Jan; 10(1):206-11. PubMed ID: 25654728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of continuous infusion of Rh-endostatin combined with platinum-based chemotherapy for advanced triple-negative breast cancer.
    Tan A; Wang H; Nong L; Jia Y; Liu Y; Zhong W; Qin F; Wang H; Tang J; Zhou W; Lu Y; Xie W
    Ann Palliat Med; 2021 Dec; 10(12):12101-12112. PubMed ID: 35016411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer.
    Fu S; Huang H; Shang K; Tu G; Zhong P; Li S; Zhu X; Peng S; Liu Y; Lu Z; Chen L
    Future Oncol; 2023 Jan; 19(2):147-158. PubMed ID: 36779488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of immune checkpoint inhibitors plus recombinant human endostatin therapy as second-line treatment in advanced non-small-cell lung cancer with negative driver gene: a pilot study.
    Yang B; Li Y; Deng J; Yang H; Sun X
    Front Oncol; 2023; 13():1210267. PubMed ID: 38023216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer.
    Lv W; Pei X; Zhao W; Cong Y; Wei Y; Li T; Zhang H; Lin Z; Saito Y; Kim JJ; Liang Z; Zhong B; Wang Z
    Transl Lung Cancer Res; 2022 Feb; 11(2):201-212. PubMed ID: 35280309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer.
    Zhao X; Mei K; Cai X; Chen J; Yu J; Zhou C; Li Q
    Invest New Drugs; 2012 Jun; 30(3):1144-9. PubMed ID: 21225314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC.
    Huang H; Zhong P; Zhu X; Fu S; Li S; Peng S; Liu Y; Lu Z; Chen L
    Front Oncol; 2023; 13():1137224. PubMed ID: 37035161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer.
    Chen L; Tong F; Peng L; Huang Y; Yin P; Feng Y; Cheng S; Wang J; Dong X
    Radiother Oncol; 2022 Sep; 174():44-51. PubMed ID: 35788355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic contrast-enhanced MRI to predict response to vinorelbine-cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial.
    Zhang R; Wang ZY; Li YH; Lu YH; Wang S; Yu WX; Zhao H
    Lancet; 2016 Oct; 388 Suppl 1():S95. PubMed ID: 27968915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Zhong Q; Liu Z
    Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety of rh-endostatin combined with chemotherapy versus chemotherapy alone for advanced NSCLC: a meta-analysis review].
    Cao D; Ge W; Wang H; Zhang L; Zheng Y; Zhang J
    Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):404-13. PubMed ID: 21569645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data.
    Zhang X; Jin F; Jiang S; Cao J; Meng Y; Xu Y; ChunmengWang ; Chen Y; Yang H; Kong Y; Liu X; Luo Z
    Invest New Drugs; 2022 Apr; 40(2):453-460. PubMed ID: 34731354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.